<tei>
    <teiHeader>
        <fileDesc xml:id="_346071162287.pdf"/>
    </teiHeader>
    <text xml:lang="en">


        <figure type="table">

            <head>Board accepted in 2004 a VCU from Sanofi Synthelabo for Fasturtec® (treatment and<lb/> </head>
<lb/> 
            <table>9<lb/> Guidelines for this scientific review, for the categorisation of drugs and for manufacturers&apos; submissions are<lb/> published in the Compendium of Guidelines, Policies and Procedures issued by PMPRB (PMPRB, 2003,<lb/> Chap 3, pp. 22-29).<lb/> 10<lb/> See http://www.pmprb-cepmb.gc.ca/english/view.asp?x=117&amp;mp=68 .<lb/> 11<lb/> The US Federal Supply Schedule presents prices negotiated between manufacturers and the US<lb/> Department of Veterans Affairs. The listed prices do not represent average paid prices in the United States,<lb/> but are among the lowest prices in the United States.</table>
        </figure>


        <figure type="table">

            <table>Source: PMPRB, 2006a.<lb/> 1.23<lb/> 1.17<lb/> 1.08<lb/> 1.13 1.14 1.11 1.06<lb/> 0.99<lb/> 0.93 0.9 0.89 0.88 0.89<lb/> 0.92<lb/> 0.95<lb/> 1.01<lb/> 0.95 0.91 0.92<lb/> 0<lb/> 0.2<lb/> 0.4<lb/> 0.6<lb/> 0.8<lb/> 1<lb/> 1.2<lb/> 1.4 2 0 0 0<lb/> 2 0 0 1<lb/> 2 0 0 2<lb/> 2 0 0 3<lb/> 2 0 0 4<lb/> 2 0 0 5<lb/> 12<lb/> The PMPRB amended its guidelines, effective in 1994, because of concerns that Canadian prices remained<lb/> 10% above the international median in the early 1990s.<lb/> 13<lb/> This figure is computed as the geometric mean of individual Canadian-to-median foreign price ratios,<lb/> weighted by Canadian sales. 30.<lb/> The key question is whether manufacturers would set higher list prices in Canada absent the<lb/> PMPRB. One study found that Canadian drug prices in 1999</table>
        </figure>


        <figure type="table">

            <figDesc>same drug.<lb/> </figDesc>
<lb/> 
            <table>14<lb/> Personal communication with representatives of Rx&amp;D, the association of research-based, brand-name<lb/> companies.<lb/> 15<lb/> The PMPRB launched a consultation process in May 2006 in order to revise its guidelines for excessive<lb/> price assessment, in which the Board raises the question of a more refined categorisation of drugs<lb/> (PMPRB, 2006d).</table>
        </figure>


        <figure type="table">

            <head>Table </head>
 
            <label>1</label>

            <head>. Formulary listing of new products by provinces<lb/> </head>
<lb/> 
            <table>% of New Drugs Reimbursed*<lb/> Average Time to Listing (in days)**<lb/> June 1, 2004 to May 31, 2006<lb/> June 1, 2004 to May 31, 2006<lb/> Alberta<lb/> 19%<lb/> 293<lb/> British Columbia<lb/> 15%<lb/> 371<lb/> Manitoba<lb/> 25%<lb/> 422<lb/> New Brunswick<lb/> 8%<lb/> 547<lb/> Newfoundland and Labrador<lb/> 10%<lb/> 298<lb/> Nova Scotia<lb/> 17%<lb/> 341<lb/> Ontario<lb/> 13%<lb/> 417<lb/> Prince Edward Island<lb/> 9%<lb/> 632<lb/> Quebec<lb/> 31%<lb/> 361<lb/> Saskatchewan<lb/> 24%<lb/> 381<lb/> Source: IMS Health. Provincial Reimbursement Advisor.<lb/> * Listings for Single-Source Products Launched June 1, 2004 to May 31, 2006.<lb/> ** Average Time to Listing for Full and Restricted Listings June 1, 2004 to May 31, 2006.</table>
        </figure>


        <figure type="table">

            <head>Box </head>
 
            <label>4</label>

            <head>).<lb/> </head>
<lb/> 
            <table>25<lb/> For instance, intravenous cancer drugs are covered through hospital global budgets in Québec, Prince<lb/> Edward Island, New Brunswick and Nova Scotia while they are covered by separate cancer agencies&apos; drug<lb/> budgets in British Columbia, Newfoundland and Saskatchewan. Provincial programs covering prescription<lb/> drugs provide different levels of coverage for new oral cancer drugs. Manitoba, Ontario, Québec and Nova<lb/> Scotia were found to cover only partially new oral drugs for ambulatory and home care, while Alberta,<lb/> Prince Edward Island and New Brunswick do not cover them at all.</table>
        </figure>


        <figure type="table">

            <head>Table </head>
 
            <label>2</label>

            <head>. Formulas used by public plans to reimburse drugs and related pricing policies<lb/> </head>
<lb/> 
            <table>Reimbursement of drugs by the public<lb/> plan<lb/> Special pricing policies<lb/> British<lb/> Columbia<lb/> Actual acquisition cost (capped to a<lb/> maximum price) + wholesaler&apos;s mark up<lb/> (capped at 7%) + dispensing fee (capped<lb/> to a maximum)</table>
        </figure>


        <figure type="table">

            <table>Saskatchewan<lb/> Actual acquisition cost + mark-up<lb/> allowance (three-tiered scale markup<lb/> ranging from 30% to 10%) + dispensing<lb/> fee (capped to $8.21).<lb/> Lowest cost alternative in generic groups<lb/> Standing-offer contracts for generics<lb/> Maximum allowable costs (reference price) since July<lb/> 2004, only for proton pump inhibitors – to be<lb/> expanded.<lb/> Alberta<lb/> Actual acquisition cost + Professional<lb/> fee (three-tiered mark-up ranging from<lb/> CAN$10.22 to CAN$20.94) + inventory<lb/> allowance (three-tier sliding scale, ranging<lb/> from CAN$0.71 to $5.03).<lb/> Lowest cost alternative within generic groups<lb/> Maximum allowable cost (reference price) in groups of<lb/> interchangeable drugs<lb/> Generic price capped at 75% of the original product<lb/> price<lb/> Manitoba<lb/> Actual acquisition cost + Professional<lb/> fees<lb/> Nova Scotia<lb/> Actual acquisition cost + Professional<lb/> fees (two-tiered markup ranging from<lb/> CAN$10.42 to CAN$15.64) + 10% for<lb/> some products.<lb/> Maximum allowable cost price for interchangeable<lb/> products, primarily generic drug products<lb/> New Brunswick Actual acquisition cost + dispensing fee<lb/> (ten-tiered, ranging from $8.40 to $161)<lb/> Maximum allowable price for generic groups<lb/> Prince Edward<lb/> Island<lb/> List price<lb/> Newfoundland<lb/> List price<lb/> Maximum allowable cost for 11 generic groups of<lb/> over-the-counter drugs<lb/> Québec<lb/> &quot; Acquisition price &quot; , which is either the<lb/> price guaranteed by the manufacturer for<lb/> wholesalers or the price guaranteed for<lb/> Requires the best available price in Canada for listed<lb/> drugs sales to pharmacist + the actual wholesale<lb/> markup<lb/> 27 (capped to $20 for costly drugs).<lb/> Lowest cost alternative in generic groups after 15<lb/> years of exclusivity for the original product. If the<lb/> brand-name product patent expires before the end of<lb/> 15 years, generic entries are reimbursed according to<lb/> the lowest cost rule, but the originator product is still<lb/> reimbursed at the original rate.<lb/> Ontario<lb/> List price + mark up + Pharmacist fee<lb/> Price-volume agreements with manufacturers<lb/> Generic price capped at 50% of the original product<lb/> price<lb/> NIHB<lb/> Acquisition cost + mark-up + pharmacist<lb/> fee<lb/> Best price alternative in generic group and in<lb/> reference price groups when applicable in the<lb/> province.<lb/> Sources: Morgan et al., 2003 and provincial drug plan websites.</table>
        </figure>


        <figure type="table">

            <table>Source: Fraser Group/Tristat Resources, 2002<lb/> 20%<lb/> 0%<lb/> 13%<lb/> 30%<lb/> 12%<lb/> 25%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 5%<lb/> 0%<lb/> 3%<lb/> 0%<lb/> 18%<lb/> 8%<lb/> 25%<lb/> 24%<lb/> 29%<lb/> 28%<lb/> 57%<lb/> 2%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 0%<lb/> 27%<lb/> 28%<lb/> 24%<lb/> 27%<lb/> 0%<lb/> 0%</table>
        </figure>


        <figure type="table">

            <head>Canada&apos;s Premiers and Territorial Leaders (the First Ministers from each<lb/> </head>
<lb/> 
            <table>31<lb/> &quot; Sicker adults &quot; are adults who rated their health as fair or poor, who had a serious illness, injury or<lb/> disability that required intensive medical care in the past two years.<lb/> 32<lb/> Québec would maintain its own program and would receive compensation comparable to the costs of the<lb/> program put in place in other provinces and territories. province or territory) in July 2004, but was not kept on the agenda of the new National Pharmaceuticals<lb/> Strategy (NPS) defined for Canada in September 2004 (see Box 7).<lb/> Box 7. Developing a new national strategy for pharmaceuticals in Canada<lb/> In September 2004, First Ministers agreed to a National Pharmaceuticals Strategy. They agreed that no Canadian<lb/> should suffer undue financial hardship in accessing needed</table>
        </figure>


        <figure type="table">

            <table>-prescribing; accelerate access to non-patented drugs and achieve international<lb/> parity on prices of non-patented drugs; and enhance analysis of cost-drivers and cost-effectiveness, including best<lb/> practices in drug plan policies.<lb/> A public report on NPS progress was issued on September 21,2006. See http://www.hc-sc.gc.ca/hcs-sss/pubs/care-<lb/>soins/2006-nps-snpp/index_e.html<lb/> 102.<lb/> In a recent paper, Marchildon (2005)</table>
        </figure>


        <figure type="table">

            <label>104</label>

            <head>.<lb/> The Canadian Agency for Drugs and Technology in Health (CADTH) 33 is responsible for<lb/> furnishing Canada&apos;s federal, provincial and territorial health care decision makers 34 (with the exception of<lb/> </head>
<lb/> 
            <table>33<lb/> Until April 2006, the CADTH was known as the Canadian Coordinating Office for Health Technology<lb/> Assessment (CCOHTA). The name change was intended to better reflect the organisation&apos;s mandate and<lb/> activities.<lb/> 34<lb/> Specific target audiences for the work include drug plan managers, regional health authorities, federal and<lb/> provincial government policy makers, hospital administrators and healthcare professionals. Québec) with assessments of the evidence and advice about the effectiveness and efficiency of drugs and<lb/> other health technologies. In addition to responsibility for the Common Drug Review (discussed above),<lb/> the agency has two other main areas of work in the field of pharmaceuticals: health technology assessment<lb/> and promotion of best practices in drug prescribing and use.</table>
        </figure>


        <figure type="table">

            <figDesc>38<lb/> A regime of compulsory licensing allows generic manufacturers to make and sell generic versions of<lb/> patented drugs before patent expiry, in exchange for royalty payments to patent holders,<lb/> 39<lb/> These amendments also introduced the prices regulatory body, which later became the PMPRB.<lb/> 40<lb/> As of May 2005, Canada permits compulsory licenses to be issued to manufacturers to produce certain<lb/> drugs for export to a developing country for treatment of designated public health problems (e.g.,<lb/> HIV/AIDS, tuberculosis, malaria and other epidemics), providing the ability for Canada to export generic<lb/> versions of patent-protected drugs to eligible importing countries unable to manufacture their own. [See<lb/> http://www.ictsd.org/weekly/03-10-15/story5.htm]. products up to six months before patent expiry, but Canada repealed this provision to comply with a World<lb/> Trade Organisation ruling against it.<lb/> 124.<lb/> However, to prevent generic manufacturers from selling their approved drugs before patent<lb/> expiry, Bill C-91 introduced the Patented Medicines (Notice of compliance) Regulations. This provision<lb/> requires patentees to provide Health Canada with</figDesc>
        </figure>


        <figure type="table">

            <figDesc>list.<lb/> 128.<lb/> Health Canada&apos;s amendments to the Food and Drug Regulations address the issue of data<lb/> protection for pharmaceuticals and bio-pharmaceuticals. Both the World Trade Organization (WTO)<lb/> Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and the North American<lb/> 41<lb/> See http://canadagazette.gc.ca/partII/2006/20061018/html/sor241-e.html.<lb/> 42<lb/> This approach is inspired by recent amendments in the United States in response to similar strategic<lb/> behaviour on the part of brand-name companies there. Free Trade Agreement (NAFTA) require that test data be protected from unfair commercial use. NAFTA<lb/> defines a minimum period of time for the protection as &quot; not less than five years &quot; . The amended regulations<lb/> provide 8 years of data protection for new and innovative drugs from</figDesc>
        </figure>


        <figure type="table">

            <figDesc>.<lb/> 43<lb/> Other products experienced very long periods of market exclusivity (24 to 36 years), but in these cases, the<lb/> relative roles of regulation and attractiveness of the market for generics cannot be easily distinguished.<lb/> 44<lb/> BioteCanada is a not-for-profit association representing the interests of biotech companies. However,<lb/> BioteCanada (2004)44 calls for the implementation of such a policy in order to take advantage of the good<lb/> development of the biotech industry in Canada to develop biotech orphan drugs.<lb/> 45<lb/> This overview relies on a summary presented in the forthcoming OECD Economic Survey of Canada 2006. 132.<lb/> One of the first goals of this policy was to increase public and private expenditures on R&amp;D with<lb/> the target of ranking among the top five countries in the world in terms of R&amp;D performance by 2010. In<lb/> the health field, R&amp;D expenditures have increased faster than in other sectors since the 1990s and now<lb/> represent a larger share of total gross domestic expenditures on R&amp;D (23% in 2005 versus 15% in 1990).<lb/> In 2005, gross domestic expenditures on R&amp;D</figDesc>
        </figure>


        <figure type="table">

            <figDesc>136.<lb/> Canada spent CAN$24.8 46 billion for drugs in 2005, i.e., CAN$ 770 per capita (CIHI, 2006).<lb/> These expenditures represent 17.5% of total health expenditures and 1.9% of Canada&apos;s GDP.</figDesc>
        </figure>


        <figure type="table">

            <figDesc>Public<lb/> Private<lb/> 137.<lb/> In 2003, Canada ranked third among OECD countries in expenditure per capita on<lb/> pharmaceuticals, far behind the United States and France but 65% above the OECD average (Figure 4).<lb/> 46<lb/> This estimated total represents the final cost to consumers, including dispensing fees, mark-ups, and<lb/> appropriate taxes. Total drug expenditure includes expenditure on prescribed drugs and non-prescribed<lb/> drugs (over-the-counter drugs and personal health supplies). The figure does not reflect expenditure on<lb/> drugs dispensed to hospital inpatients. Canadian drug expenditures represent a relatively high share of the country&apos;s GDP in comparison with<lb/> most OECD countries, except for the United States, France, Italy and those Eastern European countries<lb/> that have experienced very rapid recent growth in drug expenditures (see</figDesc>
        </figure>


        <figure type="table">

            <table>0.5<lb/> 1<lb/> 1.5<lb/> 2<lb/> 2.5<lb/> % in GDP<lb/> % of total health spending<lb/> % of pharmaceutical expenditure in GDP<lb/> </table>
<lb/> 
            <figDesc>138.<lb/> Expenditures vary widely across Canadian jurisdictions, ranging from CAN$ 481 per capita in<lb/> Nunavut to CAN$ 836 per capita in Ontario and New Brunswick (See Table 3).<lb/> 139.<lb/> Cross-provincial differences have been analysed using IMS data on sales of prescription<lb/> medicines 47 , which differ somewhat from expenditure estimates. Variations across the provinces in the<lb/> value of drug sales per person 48 were primarily the result of differences in the volume of drugs consumed,<lb/> a part of which could be explained by difference in the age structure of the population (Morgan et al.,<lb/> 47<lb/> These estimates are based on sales (at ex-manufacturer prices) of oral solid prescription drugs (which<lb/> account for about 80% of the total drug market), collected by IMS. Accordingly, average amounts by<lb/> province presented in this study do not correspond to average expenditures presented in CIHI estimates,<lb/> which include OTC drugs, mark-ups of distributors and administrative costs of public drug plans.<lb/> Moreover, deviations from the national average are significantly different in these two estimates, probably<lb/> reflecting differences in usages of OTC drugs, hospital drugs and injectibles.<lb/> 48<lb/> In 2004, prescription drug sales revenue in Canadian provinces ranged from $312 per capita in<lb/> Saskatchewan to $486 per capita in New Brunswick, a differential of 56%. 2005). Some differences across provinces were also found in the mix of drug classes and types of drugs<lb/> purchased within particular classes used, but these differences did not play a major a role in explaining<lb/> spending differences. Prices were not an important explanatory factor, as only relatively minor cross-<lb/>provincial differences in prices were found. 49</figDesc>
        </figure>


        <figure type="table">

            <head>Table</head>

            <label>3</label>

            <head>. </head>
 
            <table>Drug expenditure by province/ territory and Canada, 2005<lb/> Total drug expenditure<lb/> Public drug<lb/> expenditure<lb/> Private drug<lb/> expenditure<lb/> Prescribed drug<lb/> expenditure<lb/> Public<lb/> coverage of<lb/> prescribed<lb/> expenditure<lb/> $ million<lb/> %<lb/> THE<lb/> $ Per<lb/> capita<lb/> $ million<lb/> $ million<lb/> $ Per<lb/> capita<lb/> % TDE<lb/> % Rx exp.<lb/> New Labrador<lb/> 380.4<lb/> 16.8<lb/> 737.3<lb/> 243<lb/> 494<lb/> 630.5<lb/> 85.5<lb/> 38.6<lb/> Prince Edward<lb/> Island<lb/> 95.8<lb/> 16.7<lb/> 691.7<lb/> 194<lb/> 498<lb/> 545.5<lb/> 78.9<lb/> 35.5<lb/> Nova Scotia<lb/> 728.4<lb/> 17.2<lb/> 775.8<lb/> 242<lb/> 534<lb/> 627.7<lb/> 80.9<lb/> 38.5<lb/> New Brunswick<lb/> 628.3<lb/> 19.2<lb/> 836.0<lb/> 227<lb/> 609<lb/> 701.6<lb/> 83.9<lb/> 32.3<lb/> Québec<lb/> 5,860.5<lb/> 20.0<lb/> 775.6<lb/> 341<lb/> 435<lb/> 674.4<lb/> 86.9<lb/> 50.5<lb/> Ontario<lb/> 10,485.6<lb/> 18.2<lb/> 836.8<lb/> 313<lb/> 524<lb/> 693.2<lb/> 82.8<lb/> 45.1<lb/> Manitoba<lb/> 804.7<lb/> 14.3<lb/> 686.3<lb/> 291<lb/> 396<lb/> 571.0<lb/> 83.2<lb/> 50.9<lb/> Saskatchewan<lb/> 674.8<lb/> 15.4<lb/> 677.9<lb/> 265<lb/> 412<lb/> 554.2<lb/> 81.8<lb/> 47.9<lb/> Alberta<lb/> 2,285.0<lb/> 14.7<lb/> 707.3<lb/> 269<lb/> 438<lb/> 566.1<lb/> 80.0<lb/> 47.6<lb/> British Columbia<lb/> 2,771.3<lb/> 15.1<lb/> 651.5<lb/> 219<lb/> 432<lb/> 521.1<lb/> 80.0<lb/> 42.1<lb/> Yukon Territory<lb/> 20.9<lb/> 11.0<lb/> 667.8<lb/> 370<lb/> 298<lb/> 540.1<lb/> 80.9<lb/> 68.5<lb/> Northwest<lb/> Territories<lb/> 24.6<lb/> 8.3<lb/> 569.6<lb/> 340<lb/> 230<lb/> 485.6<lb/> 85.3<lb/> 70.0<lb/> Nunavut<lb/> 14.5<lb/> 4.5<lb/> 481.7<lb/> 259<lb/> 223<lb/> 398.4<lb/> 82.7<lb/> 65.0<lb/> Canada<lb/> 24,774.8<lb/> 17.5<lb/> 769.68<lb/> 295<lb/> 475<lb/> 640.5<lb/> 83.2<lb/> 46.0<lb/> Source: CIHI report 2006, 13</table>
        </figure>


        <figure type="table">

            <table>11.3<lb/> 9.5<lb/> 9.1<lb/> 8.6<lb/> 8.3<lb/> 7.7<lb/> 7.0<lb/> 5.8<lb/> 5.8<lb/> 5.7<lb/> 5.4<lb/> 5.3<lb/> 4.9<lb/> 4.6<lb/> 4.5<lb/> 4.2<lb/> 3.7<lb/> 3.7<lb/> 3.3<lb/> 3.3<lb/> 3.2<lb/> 1.7<lb/> 0.5<lb/> 9.7<lb/> 4.8<lb/> 4.8<lb/> 8.2<lb/> 6.1<lb/> 2.6<lb/> 3.7<lb/> 3.1<lb/> 7.8<lb/> 5.4<lb/> 5.3<lb/> 1.8<lb/> 5.1<lb/> 3.3<lb/> 3.2<lb/> 4.8<lb/> 1.5<lb/> 3.6<lb/> 2.9<lb/> 3.6<lb/> 8.1<lb/> 4.9<lb/> 3.5<lb/> 5.6<lb/> 6.9<lb/> 4.7<lb/> 5.0</table>
        </figure>


        <figure type="table">

            <label>143</label>

            <head>.<lb/> Expenditures for hospital drugs accounted for CAN$ 1.5 billion in 2003, representing 7% of<lb/> prescription drug expenditures in Canada. Again, there are wide variations across provinces, with<lb/> 50<lb/> Data are available only for Canada, Denmark, Finland, France, Germany, Japan, Korea, Slovak Republic,<lb/> Spain, and Switzerland in 2003. For these countries, the average per capita expenditures for OTC drugs is<lb/> 62 US(PPP)$ -versus 49 in Canada and the average share in total expenditures for drugs is 16% -versus<lb/> 9.6% in Canada. expenditures for hospital drugs ranging from CAN$ 37 per capita in Prince Edward Island to CAN$ 58 in<lb/> New Brunswick. Hospital drug expenditures range from an average of CAN$ 44.8 per inpatient day in<lb/> Nova Scotia to $76 in British Columbia 51 . According to IMS data on manufacturers&apos; sales in Canada 52 ,<lb/> hospital drugs accounted for 11.6% of total prescription drug sales in Canada in 2005 and the market is<lb/> growing at twice the rate of the ambulatory market (IMS Health, 2006).</head>
        </figure>


        <figure type="table">

            <figDesc>2005 period (see<lb/> CIHI, 2006, page 47 for instance). These indexes, computed with a small number of pharmaceutical<lb/> products (from 8 to 30 according to Statistics Canada&apos;s methodology), may not be representative of the<lb/> pharmaceutical market. Moreover, the more rapid increase in consumer prices reported in the non-PMPRB<lb/> indexes may be in part due to increases in distributors&apos; margins. The PMPRB&apos;s PMPI (Patented Medicines<lb/> Price Index) is a Laspeyres index, computed as a weighted-by-sales average of year-over-year changes in<lb/> ex-manufacturers&apos; prices. It is based on all patented drugs and not only on a sample.<lb/> 55<lb/> With the notable exception of Saskatchewan, which experienced high growth in generic prices in the 2001<lb/> to 2004 period, after a sharp decline between 1999 and 2001.</figDesc>
        </figure>


        <figure type="table">

            <table>109<lb/> 678<lb/> 727<lb/> 901<lb/> 1517<lb/> 2470<lb/> 2775<lb/> 3039<lb/> 3537<lb/> 4133<lb/> 5874<lb/> 6741<lb/> 7999<lb/> 8234<lb/> 12112<lb/> 12411<lb/> 24908<lb/> 25819<lb/> 35289</table>
        </figure>


        <figure type="table">

            <table>11.5% in 1998 but has since<lb/> declined to 8.3% in 2005. In 2005, 80 companies reported total R&amp;D expenditures amounting to<lb/> CAN$1.23 billion 60 , representing 8.8% of their sales (PMPRB, 2006a).<lb/> 174.<lb/> Pharmaceutical companies concentrate their R&amp;D spending in two provinces, Québec and<lb/> Ontario, which represent 45.6% and 42.9% of Canadian private R&amp;D expenditures, respectively (PMPRB,<lb/> 2005a).<lb/> 175.<lb/> International comparisons of R&amp;D expenditure data raise a number of methodological problems<lb/> and no complete statistics are available to compare investments in R&amp;D in all OECD countries (OECD,<lb/> 2005; EFPIA</table>
        </figure>


        <figure type="table">

            <table>(1.8% 64 ).<lb/> 60<lb/> Note that PMPRB figures only relate to &quot; patentees &quot; , i.e. manufacturers which have at least one patented<lb/> product. Other manufacturers, notably some generic manufacturers, also invest in R&amp;D (Industry Canada,<lb/> 2006).<lb/> 61<lb/> This is particularly evident when considering the case of Switzerland where expenditures for R&amp;D are<lb/> several times higher than domestic sales (see InterpharmaPh, 2005, p. 43 and 47).<lb/> 62<lb/> Data are not available for 14 countries, including Switzerland.<lb/> 63<lb/> Rough estimate based on figures from OECD and from the British Pharmaceutical Industry<lb/> Competitiveness Task Force (PICTF, 2006).<lb/> 64<lb/> Computed from different official sources presented in Wikipedia<lb/> (http://en.wikipedia.org/wiki/List_of_countries_by_GDP_%28PPP%29, accessed July 20, 2006)</table>
        </figure>


        <figure type="table">

            <table>Canada (PMPRB, 2005c).<lb/> 74<lb/> http://www.capdm.ca/industry_facts/facts.asp, accessed on May 14, 2006.<lb/> 75<lb/> Distribution costs defined by the PMPRB do not include pharmacists&apos; margins or fees, but only covers the<lb/> cost of &apos;intermediaries&apos; between the manufacturer and the retailer. 193.<lb/> The number </table>
 
            <head>of pharmacies in Canada has increased steadily in recent years, growing from a total<lb/> of 7,144 (1 per 4,342 people) in 2001 to 7,585 (1 per 4,212 people) in 2004. 76 During that period, the<lb/> number of independent pharmacies declined (from 2069 to 1638), while the number of chain pharmacies<lb/> increased (from 3,914 to 4,444</head>
        </figure>


        <figure type="table">

            <table>2 months) and Japan (43.9 months).<lb/> 79<lb/> The sample was composed of products for which assessment had been published in the Canadian edition of<lb/> the Medical Letter between May 12, 2003 and June 21, 2004. The therapeutic value of the drug was rated<lb/> by two clinical pharmacologists and compared with the US Food and Drug Administration (FDA) criteria<lb/> for priority review.<lb/> 80<lb/> Two other drugs belong to the first and second categories according to different indications, two others<lb/> belong to the second and third categories and two were not rated because of a lack of information.<lb/> 81<lb/> This situation is summarised in a news article by Lisa Priest, published in the Globe and Mail (2006). Health Canada&apos;s Special Access Programme. In an unusual step, Ontario has decided to reimburse the<lb/> costs of treatment for certain patients who receive the treatment in US hospitals. The price paid by Ontario<lb/> is high ($3.6 million for 34 patients treated in the 2005-2006 fiscal year), including the cost of treatments<lb/> in US hospitals on the top of the drug cost. This choice suggests a possible discrepancy between the<lb/> standards used by the PMPRB for judging when a price is excessive and the willingness-to-pay of<lb/> jurisdictions.</table>
        </figure>


        <figure type="table">

            <figDesc>; PICTF,<lb/> 2006; OECD, 2006, KPMG, quoted by Government of Canada, 2005).<lb/> 234.<lb/> Canada presents a number of attractive features for business enterprises: the proximity to the US<lb/> market, allied with NAFTA provisions easing trade with the United States: a highly educated and relatively<lb/> low-cost labour force; a lower marginal rate of corporate tax than the United States and Japan; and a high<lb/> level of access to venture capital (Government of Canada, 2006; OECD, 2006, KPMG quoted by the<lb/> government of Canada, 2005). All these elements, combined with a favourable perception among business<lb/> executives regarding Canada&apos;s business environment, contribute to a good ranking of Canada in the World<lb/> Competitiveness Yearbook of the Institute for </figDesc>
 
            <head>Management Development (7th among 61 countries, behind the United States, Hong Kong, Singapore, Iceland, Denmark and Australia) 84 (Institute for Management<lb/> Development, 2006).<lb/> </head>
<lb/> 
            <table>235.<lb/> Although pharmaceutical industry activities continue to grow in Canada, notably in terms of<lb/> production and employment (Industry Canada</table>
        </figure>


        <figure type="table">

            <figDesc>United States.<lb/> 236.<lb/> The attractiveness for R&amp;D activities is less evident: R&amp;D expenditures of companies in Canada<lb/> increased (in absolute terms) until 2002 but declined in 2003 and 2004 (PMPRB</figDesc>
        </figure>


        <figure type="table">

            <table>0.78<lb/> 0.88<lb/> 0.85<lb/> 0.96<lb/> 0.75<lb/> 0.85<lb/> 0.79<lb/> 0.73<lb/> 1.09<lb/> 0.9<lb/> 1.69<lb/> 0.85<lb/> 0.49<lb/> 0.71<lb/> 0.84<lb/> 0.76<lb/> 0.8<lb/> 0.23<lb/> 0.58<lb/> 0.99<lb/> 0.8<lb/> 0.65<lb/> 0.81<lb/> 0.75<lb/> 0.76<lb/> 0.91<lb/> 0.73<lb/> 0.72<lb/> 0.64<lb/> 0.59<lb/> 1.34<lb/> 0.87<lb/> 2.49<lb/> 0<lb/> 0.5<lb/> 1<lb/> 1.5<lb/> 2<lb/> 2.5<lb/> Australia<lb/> Finland<lb/> France<lb/> Germany<lb/> Italy<lb/> Netherlands<lb/> New<lb/> Zealand<lb/> Spain<lb/> Switzerland<lb/> United<lb/> Kingdom<lb/> Unites<lb/> States<lb/> Patented Generic Non-patented branded<lb/> 91<lb/> Foreign countries studied were the seven comparator countries less Sweden, plus Australia, Finland, the<lb/> Netherlands, New Zealand, and Spain.</table>
        </figure>


        <figure type="table">

            <head>Table</head>

            <label>4</label>

            <head>. </head>
 
            <table>Summary of findings from selected studies comparing Canadian pharmaceutical price levels with<lb/> those of other countries<lb/> Study<lb/> Price comparison<lb/> Methodology<lb/> Findings<lb/> Danzon and<lb/> Furukawa (2003)<lb/> 1999 manufacturers&apos; prices for<lb/> 249 molecules among the US<lb/> top-selling 300<lb/> Prices weighted using US<lb/> sales volume. US discounts<lb/> estimated at 8%.<lb/> Canadian prices found to be<lb/> 33% lower than US prices.<lb/> Originator products 35% lower<lb/> and generics 6% lower.<lb/> US Department<lb/> of Commerce<lb/> (2004)<lb/> 2003 manufacturers&apos; prices for<lb/> the US 54 top-selling patented<lb/> medicines<lb/> Fisher Indexes calculated<lb/> based on price per standard<lb/> unit. No adjustment for US<lb/> discounts.<lb/> Canadian prices found to be<lb/> 46% lower than US prices.<lb/> PMPRB (2005)<lb/> 2004 manufacturers&apos; prices in<lb/> Canada and seven designated<lb/> comparator countries for<lb/> patented medicines available<lb/> in both Canada and the<lb/> comparator country.<lb/> Average ratio-to-Canadian<lb/> price computed for each<lb/> product, weighted by sales in<lb/> Canada. Prices converted by<lb/> current exchange rates. US<lb/> Federal Supply Schedule<lb/> prices used as point of<lb/> comparison.<lb/> Canadian prices found to be<lb/> 44% lower than US prices.<lb/> Compared with Canada, prices<lb/> in the United Kingdom are<lb/> 13% higher; prices in<lb/> Switzerland are 16% higher;<lb/> prices in France are 10%<lb/> lower; prices in Italy are 17%<lb/> lower; Swedish and German<lb/> prices are comparable.<lb/> PMPRB (2003)<lb/> Fiscal year 1988-1989<lb/> manufacturers&apos; prices for non-<lb/>patented single-source drugs<lb/> that are available in at least<lb/> three of seven designated<lb/> comparator countries. Study<lb/> universe represents only 13%<lb/> of provincial drug<lb/> expenditures.<lb/> Average Canadian price to<lb/> median international price ratio<lb/> is computed as a geometric<lb/> mean. Findings weighted by<lb/> Canadian utilisation. (See Box<lb/> 9 for more detail on methods,<lb/> alternative calculations and<lb/> sensitivity to assumptions.)<lb/> Canadian prices for non-<lb/>patented single-source drugs<lb/> found to be 22% higher than<lb/> international median prices<lb/> and 55% above median<lb/> European prices.<lb/> When originator brand-name<lb/> products only are taken into<lb/> account in all countries,<lb/> Canadian prices are 21%<lb/> above the median international<lb/> price and 54% above median<lb/> European prices.<lb/> PMPRB (2003)<lb/> 2000 manufacturers&apos; prices for<lb/> 496 multiple-source drugs (64<lb/> molecules) representing 40%<lb/> of the generic market in six<lb/> Canadian provinces.<lb/> Bilateral comparisons made<lb/> between Canada and<lb/> designated comparator<lb/> countries.<lb/> Canadian prices for multiple-<lb/>source drugs were higher than<lb/> most comparator countries<lb/> with the exception of the<lb/> United Kingdom, Switzerland<lb/> and the United States.<lb/> Canadian prices for generics<lb/> were 35% below Canadian<lb/> brand-name products, on<lb/> average, a larger price<lb/> differential than found in most<lb/> comparator countries, with the<lb/> exception of Germany (41%),<lb/> New Zealand (47%) and the<lb/> United Kingdom (42%). Palmer D&apos;Angelo<lb/> Consulting<lb/> International<lb/> (2002)<lb/> 2001 prices for 27 top-selling<lb/> generic drugs representing<lb/> 39% of generic drug sales in<lb/> Canada. Quebec formulary<lb/> price used for Canada. Federal<lb/> Supply Schedule used for<lb/> United States.<lb/> Several methodologies used to<lb/> compute mean, median,<lb/> weighted and unweighted price<lb/> indexes.<lb/> Canadian prices for generics<lb/> were found to be above US<lb/> prices according to several<lb/> alternative methodologies<lb/> used, although choice of US<lb/> price for comparison suggests<lb/> differential is overstated.<lb/> Skinner, 2005<lb/> 2003 retail prices of top-selling<lb/> generic drugs in Canada,<lb/> bilateral comparison with the<lb/> United States<lb/> Average of ratio of Canadian<lb/> to US prices. LIST OF ACRONYMS<lb/> AAC<lb/> Actual Acquisition Cost<lb/> ABPI<lb/> Association of the British Pharmaceutical Industry<lb/> ARC<lb/> Advance Ruling Certificate<lb/> ATC<lb/> Anatomical Therapeutic Chemical<lb/> ATP<lb/> Average Transaction Price<lb/> CAPDM<lb/> Canadian Association for Pharmacy Distribution Management<lb/> CADTH<lb/> Canadian Agency for Drugs and Technology in Health<lb/> CCOHTA<lb/> Canadian Coordinating Office for Health Technology Assessment<lb/> CDR<lb/> Common Drug Review<lb/> CEDAC<lb/> Canadian Expert Drug Advisory Committee<lb/> CGPA<lb/> Canadian Generic Pharmaceutical Association<lb/> CLIHA<lb/> Canadian Life and Health Insurance Association<lb/> CMA<lb/> Canadian Medical Association<lb/> COMPUS<lb/> Canadian Optimal Medication Prescribing and Utilisation Service<lb/> CPSI<lb/> Canadian Patient Safety Institute<lb/> DBL<lb/> Drug Benefit List<lb/> DDD<lb/> Defined Daily Dose<lb/> DQTC<lb/> Drug Quality and Therapeutics Committee<lb/> DTCA<lb/> Direct-to-consumer-advertising<lb/> DURs<lb/> Drug Utilisation Reviews<lb/> FDA<lb/> Food and Drug Administration<lb/> FP&amp;TC<lb/> Federal Pharmacy and Therapeutics Committee<lb/> FSS<lb/> Federal Supply Schedule<lb/> GATT<lb/> General Agreement on Tariffs and Trade<lb/> HDAP<lb/> Human Drug Advisory Panel<lb/> HPFB<lb/> Health Products and Food Branch<lb/> ICR<lb/> Individual Clinical Review<lb/> NAFTA<lb/> North American Free Trade Agreement<lb/> NCE<lb/> New Chemical Entities<lb/> NIHB<lb/> Non-insured Health Benefits<lb/> NOC<lb/> Notice of Compliance<lb/> NOC/c<lb/> Notice of Compliance with Conditions<lb/> NPS<lb/> National Pharmaceuticals Strategy<lb/> ODB<lb/> Ontario Drug Benefit<lb/> OTC<lb/> Over-the-counter<lb/> PAAB<lb/> Pharmaceutical Advertising Advisory Board<lb/> PDMA<lb/> Prescription Drug Marketing Act<lb/> PICTF<lb/> Pharmaceutical Industry Competitiveness Task Force<lb/> PMPI<lb/> Patented Medicines Price Index<lb/> PMPRB<lb/> Patented Medicine Prices Review Board<lb/> PPPs<lb/> Purchasing Power Parities PRA<lb/> Provincial Reimbursement Advisor<lb/> SAP<lb/> Special Access Programme<lb/> SR&amp;D<lb/> Scientific Research &amp; Development<lb/> VCU<lb/> Voluntary Compliance Undertaking<lb/> WTO<lb/> World Trade Organisation No. 5<lb/> STROKE CARE IN OECD COUNTRIES: A COMPARISON OF TREATMENT, COSTS AND<lb/> OUTCOMES IN 17 COUNTRIES (2003) Lynelle Moon, Pierre Moïse, Stéphane Jacobzone and<lb/> the ARD-Stroke Experts Group<lb/> No. 4<lb/> SURVEY OF PHARMACOECONOMIC ASSESSMENT ACTIVITY IN ELEVEN COUNTRIES<lb/> (2003) Michael Dickson, Jeremy Hurst and Stéphane Jacobzone<lb/> No. 3<lb/> OECD STUDY OF CROSS-NATIONAL DIFFERENCES IN THE TREATMENT, COSTS AND<lb/> OUTCOMES OF ISCHAEMIC HEART DISEASE (2003) Pierre Moise, Stéphane Jacobzone and<lb/> the ARD-IHD Experts Group<lb/> No. 2<lb/> INVESTMENT IN POPULATION HEALTH IN FIVE OECD COUNTRIES (2003) Jan Bennett<lb/> No. 1<lb/> PHARMACEUTICAL USE AND EXPENDITURE FOR CARDIOVASCULAR DISEASE AND<lb/> STROKE: A STUDY OF 12 OECD COUNTRIES (2003) Michael Dickson and Stéphane<lb/> Jacobzone<lb/> RECENT RELATED OECD PUBLICATIONS:<lb/> OECD HEALTH DATA 2006 (2006), available in English, French, German, Italian, Russian and Spanish<lb/> on CDROM (Windows 98/2000/NT/Me/XP); online version features these languages, plus Japanese<lb/> OECD REVIEW OF HEALTH SYSTEMS – SWITZERLAND (2006)<lb/> OECD REVIEWS OF HEALTH SYSTEMS – FINLAND (2005)<lb/> HEALTH AT A GLANCE – OECD INDICATORS 2005 (2005), published biennially<lb/> LONG-TERM CARE FOR OLDER PEOPLE (2005), OECD Health Project series<lb/> HEALTH TECHNOLOGIES AND DECISION MAKING (2005), OECD Health Project series<lb/> OECD REVIEWS OF HEALTH SYSTEMS – MEXICO (2005)<lb/> TOWARDS HIGH-PERFORMING HEALTH SYSTEMS (2004), OECD Health Project series<lb/> TOWARDS HIGH-PERFORMING HEALTH SYSTEMS: POLICY STUDIES (2004), OECD Health Project<lb/> series<lb/> PRIVATE HEALTH INSURANCE IN OECD COUNTRIES (2004), OECD Health Project series<lb/> A DISEASE-BASED COMPARISON OF HEALTH SYSTEMS: What is Best and at What Cost? (2003)<lb/> OECD REVIEWS OF HEALTH CARE SYSTEMS – KOREA (2003)<lb/> POVERTY AND HEALTH (2003)<lb/> ASSESSING MICROBIAL SAFETY OF DRINKING WATER: IMPROVING APPROACHES AND<lb/> METHODS (2003)<lb/> MEASURING UP: IMPROVING HEALTH SYSTEM PERFORMANCE IN OECD COUNTRIES (2002)<lb/> MEASURING EXPENDITURE ON HEALTH-RELATED R&amp;D (2001)<lb/> A SYSTEM OF HEALTH ACCOUNTS (2000)</table>
        </figure>



    </text>
</tei>

